fucose and refludan
fucose has been researched along with refludan in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bologna, L; Da Roit, F; Ferrara, C; Golay, J; Introna, M; Klein, C; Leusen, JH; Rambaldi, A | 1 |
Other Studies
1 other study(ies) available for fucose and refludan
| Article | Year |
|---|---|
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibody Affinity; Antigens, CD20; CD11b Antigen; Fucose; Glycosylation; GPI-Linked Proteins; Hirudins; Humans; Interleukin-6; Interleukin-8; L-Selectin; Leukemia, Lymphocytic, Chronic, B-Cell; Neutrophil Activation; Phagocytosis; Protein Engineering; Protein Isoforms; Receptors, IgG; Recombinant Proteins; Rituximab; Surface Plasmon Resonance; Tumor Necrosis Factor-alpha; Up-Regulation | 2013 |